Johnson, Chris

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet

Retinal Development and DisordersVirus-based gene therapy research

Cited by 1,952

Clinical Trial of Lutein in Patients With Retinitis Pigmentosa Receiving Vitamin A

Berson, E. L., ROSNER, B. A., Sandberg, M. A., Weigel-DiFranco, C., Brockhurst, R. J., Hayes, K. C., Johnson, E. J., Anderson, E. J., Johnson, C. A., Gaudio, A. R., et al. (2010) · Archives of Ophthalmology

Retinal Development and DisordersRetinal Diseases and Treatments

Cited by 179

Age-related changes in the central visual field for short-wavelength-sensitive pathways

Johnson, C. A., Adams, A. J., Twelker, J. D., & Quigg, J. M. (1988) · Journal of the Optical Society of America A

Visual perception and processing mechanismsRetinal Development and Disorders

Cited by 132

Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy

Maguire, M. G., Liu, D., Glassman, A. R., Jampol, L. M., Johnson, C. A., Baker, C. W., Bressler, N. M., Gardner, T. W., Pieramici, D., Stockdale, C. R., et al. (2020) · JAMA Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 61

International AI Safety Report

Bengio, Y., Mindermann, S., Privitera, D., Besiroglu, T., Bommasani, R., Casper, S., Choi, Y., Fox, P., Garfinkel, B., Goldfarb, D., et al. (2025) · arXiv

Ethics and Social Impacts of AISafety Systems Engineering in Autonomy

Cited by 16